{
"id":"mk19_b_hm_s6",
"subspecialtyId":"hm",
"title":"Platelet Disorders",
"jsonContent":{
"type":"section",
"id":"mk19_b_hm_s6",
"title":{
"__html":"Platelet Disorders"
},
"titleNode":{
"type":"section-title",
"hlId":"aa5bc3",
"children":[
"Platelet Disorders"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_hm_s6_1",
"title":{
"__html":"Normal Platelet Physiology"
},
"titleNode":{
"type":"section-title",
"hlId":"8da34c",
"children":[
"Normal Platelet Physiology"
]
},
"children":[
{
"type":"p",
"hlId":"422c7d",
"children":[
"Platelets are megakaryocyte fragments circulating in an inactive state for 8 to 10 days, with 30% sequestered in the spleen (released in response to stress). Activation is a three-stage process: adherence (mediated by von Willebrand factor [vWF]), activation with shape change (resulting in the release of clotting and inflammatory substances), and aggregation. Platelet aggregation is reversible following fibrinogen binding but irreversible after released arachidonic acid is converted into thromboxane A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
". Aspirin irreversibly acetylates and inactivates thromboxane A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
", and clopidogrel irreversibly binds to the P2Y",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"12"
]
},
" adenosine diphosphate receptor, blocking platelet activation and aggregation. Intravenous agents such as abciximab, eptifibatide, and tirofiban inhibit fibrinogen binding. Platelets also provide the phospholipid membrane for the coagulation cascade (see ",
{
"type":"cross-reference",
"target":"mk19_b_hm_s7_1",
"children":[
"Bleeding Disorders"
]
},
")."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s6_2",
"title":{
"__html":"Approach to the Patient With Thrombocytopenia"
},
"titleNode":{
"type":"section-title",
"hlId":"329198",
"children":[
"Approach to the Patient With Thrombocytopenia"
]
},
"children":[
{
"type":"p",
"hlId":"fd61a7",
"children":[
"Thrombocytopenia must be evaluated according to the platelet count and the clinical setting. Platelet counts greater than 100,000/μL (100 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L) are safe. Counts greater than 50,000/μL (50 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L) do not require treatment and are adequate for surgical procedures, although 100,000/μL (100 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L) is desirable for neurosurgery. Counts less than 50,000/μL (50 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L) should be corrected before surgeries with significant bleeding risk, and counts less than 10,000/μL (10 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L) are associated with risk of spontaneous bleeding. Concomitant use of drugs that impair platelet function increase bleeding risk from thrombocytopenia."
]
},
{
"type":"p",
"hlId":"606100",
"children":[
"Evaluation begins with a review of the peripheral blood smear to confirm the count. Pseudothrombocytopenia occurs if patients have antibodies to ethylenediaminetetraacetic acid, causing platelets to clump together in vitro ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_hm_f23",
"wrapId":"1",
"children":[
"Figure 23"
]
}
]
},
")"
]
},
". An accurate count can be obtained from blood drawn in citrate or heparin. Inaccurate machine counts may occur if the platelets are exceptionally large (mistaken for erythrocytes, which falsely lowers the count) or if erythrocyte fragments (schistocytes) are counted as platelets (falsely elevated counts)."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_b_hm_f23"
]
},
{
"type":"p",
"hlId":"3ebb37",
"children":[
"Symptoms include mucocutaneous bleeding (epistaxis, gum bleeding, menorrhagia, hematuria, melena, or hematochezia) and easy bruising. A thorough review of medications and supplements is required. Drug and alcohol exposure must be documented and dietary restrictions noted (vegans may be deficient in vitamin B",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"12"
]
},
"). Related disorders, such as HIV infection, hepatitis C infection, or thyroid diseases must be evaluated."
]
},
{
"type":"p",
"hlId":"e926e6",
"children":[
"The physical examination may reveal blood blisters in the mouth (wet purpura), petechiae or ecchymoses, or splenomegaly."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s6_3",
"title":{
"__html":"Thrombocytopenic Disorders"
},
"titleNode":{
"type":"section-title",
"hlId":"0bc672",
"children":[
"Thrombocytopenic Disorders"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_hm_s6_3_1",
"title":{
"__html":"Decreased Production"
},
"titleNode":{
"type":"section-title",
"hlId":"2791d3",
"children":[
"Decreased Production"
]
},
"children":[
{
"type":"p",
"hlId":"757aa6",
"children":[
"Disorders associated with bone marrow infiltration (myelofibrosis, metastatic tumors, granulomatous diseases) can decrease platelet production, as can nutritional deficiencies (vitamin B",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"12"
]
},
" or folate) or abnormalities in stem cell maturation (aplastic anemia and myelodysplasia). Other cytopenias often accompany the low platelet count."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s6_3_2",
"title":{
"__html":"Increased Destruction"
},
"titleNode":{
"type":"section-title",
"hlId":"c459e1",
"children":[
"Increased Destruction"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_hm_s6_3_2_1",
"title":{
"__html":"Non–Immune-Mediated Thrombocytopenia"
},
"titleNode":{
"type":"section-title",
"hlId":"91bbab",
"children":[
"Non–Immune-Mediated Thrombocytopenia"
]
},
"children":[
{
"type":"p",
"hlId":"810656",
"children":[
"Splenomegaly is a common medical problem that causes thrombocytopenia through increased sequestration without actual platelet destruction. The thrombocytopenia is usually associated with anemia and leukopenia."
]
},
{
"type":"p",
"hlId":"c9956e",
"children":[
"Unlike sequestration, nonimmune platelet destruction may be caused by abnormal platelet aggregation occurring in the setting of disseminated intravascular coagulation or microangiopathic hemolytic anemia (MAHA)."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s6_3_2_2",
"title":{
"__html":"Immune Thrombocytopenic Purpura"
},
"titleNode":{
"type":"section-title",
"hlId":"d317ba",
"children":[
"Immune Thrombocytopenic Purpura"
]
},
"children":[
{
"type":"p",
"hlId":"d89dca",
"children":[
"Immune thrombocytopenic purpura (ITP) is caused by autoantibodies to platelet surface membranes. Diagnosis requires a platelet count of less than 100,000/μL (100 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L). ITP can be a primary diagnosis or occur secondary to other disorders such as systemic lupus erythematosus, chronic lymphocytic leukemia, HIV, hepatitis C, and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Helicobacter pylori"
]
},
" infection. Drugs can also induce immune platelet destruction."
]
},
{
"type":"p",
"hlId":"66061c",
"children":[
"Acute, persistent, and chronic ITP are defined as lasting less than 3 months, 3 to 12 months, and more than 12 months, respectively. Many patients are asymptomatic until the platelet count decreases to less than 10,000/μL (10 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L). Petechiae and ecchymoses without splenomegaly are notable physical signs. Laboratory findings are limited to a low platelet count. Testing for HIV and hepatitis C should be performed. Bone marrow evaluation is not necessary unless clinical findings suggest an alternate diagnosis. Platelet autoantibody testing is not recommended because the test is neither sensitive nor specific enough to play a major role in establishing the diagnosis, and results do not correlate with clinical outcomes."
]
},
{
"type":"p",
"hlId":"d63376",
"children":[
"In adults with newly diagnosed ITP who are asymptomatic or have minor mucocutaneous bleeding and also have a platelet count less than 30,000/μL (30 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L), treatment with glucocorticoids is recommended. Asymptomatic patients or those with minor mucocutaneous bleeding with a platelet count greater than 20,000/μL (20 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L) may be managed as outpatients. Recommended initial therapy includes a short course (<6 weeks) of prednisone or dexamethasone. The response to intravenous immune globulin is faster and may be indicated in patients with more severe thrombocytopenia and life-threatening bleeding. Complications from glucocorticoids include mood disorders, insomnia, fluid retention, hyperglycemia, and hypertension. Complications from intravenous immune globulin include infusion reactions (headache, chills, anaphylaxis), kidney disease, and thrombosis. Patients who relapse or have ITP refractory to these treatments require second-line treatments, such as splenectomy, rituximab, and thrombopoietin receptor agonists."
]
},
{
"type":"p",
"hlId":"0b0598",
"children":[
"Thrombopoietin receptor agonists (e.g., daily oral eltrombopag or avatrombopag; weekly subcutaneous romiplostim) may be beneficial but must be taken continuously to prevent relapse. Splenectomy is advised for patients who are unresponsive to or intolerant of medical management but should be delayed for 1 year after diagnosis because of the possibility of delayed remission."
]
},
{
"type":"p",
"hlId":"903a25",
"children":[
"Because patients with chronic ITP may be asymptomatic, treatment decisions must balance the risk of bleeding against treatment-related toxicities."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"4f3739",
"hvc":true,
"children":[
"Antiplatelet antibody testing is neither sensitive nor specific enough to establish the diagnosis of immune thrombocytopenic purpura and should not be performed."
]
},
{
"type":"keypoint",
"hlId":"6be8d6",
"children":[
"Treatment for acute immune thrombocytopenic purpura is instituted with glucocorticoids or intravenous immune globulin when patients become symptomatic or if the platelet count decreases to less than 30,000/μL (30 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L); asymptomatic patients with higher platelet counts can be managed with careful observation."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s6_3_2_3",
"title":{
"__html":"Heparin-Induced Thrombocytopenia"
},
"titleNode":{
"type":"section-title",
"hlId":"cd2a63",
"children":[
"Heparin-Induced Thrombocytopenia"
]
},
"children":[
{
"type":"p",
"hlId":"5847a4",
"children":[
"Type I heparin-induced thrombocytopenia (HIT) refers to a non−immune-mediated decrease in platelets occurring within the first few days of exposure to heparin. No intervention is needed. Type II HIT is an immune-mediated thrombocytopenia occurring 5 to 10 days after exposure. It is caused by antibodies against platelet factor 4 (complexed to heparin). Associated thrombosis, which includes deep venous thrombosis, pulmonary embolism, or more unusual acute arterial occlusions, can be life threatening. The risk is highest with unfractionated heparin compared with low-molecular-weight heparin. Most patients with HIT develop platelet counts less than 150,000/μL (150 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L), but severe thrombocytopenia is unusual. In patients with high baseline platelet counts, a decrease of greater than 50% warrants concern. Skin necrosis at the site of heparin injection or progressive thromboembolic events in patients receiving heparin are signs of possible HIT, even if the platelet count remains normal. The 4T scoring system ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t19",
"wrapId":"2",
"children":[
"Table 19"
]
}
]
},
")"
]
},
" is useful for estimating the likelihood of HIT and the need for discontinuing heparin while definitive tests are pending."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_b_hm_t19"
]
},
{
"type":"p",
"hlId":"4fffc4",
"children":[
"The enzyme-linked immunosorbent assay for platelet factor 4 antibodies is a very sensitive screening test for HIT (a negative test result rules out the diagnosis) but is not specific. Confirmation requires either the serotonin release assay or the heparin-induced platelet aggregation assay ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_hm_f24",
"wrapId":"3",
"children":[
"Figure 24"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_b_hm_f24"
]
},
{
"type":"p",
"hlId":"494522",
"children":[
"A HIT diagnosis requires immediate heparin discontinuation. An alternate anticoagulant should then be started (unless the patient is actively bleeding). Argatroban, bivalirudin, danaparoid, fondaparinux, or a direct oral anticoagulant (such as rivaroxaban) are alternative options. Warfarin should not be the initial alternate anticoagulant because antithrombotic efficacy requires 3 to 5 days of therapy, during which time declining levels of protein C increase the thrombotic risk. Transitioning to warfarin is safe after thrombocytopenia resolves. Anticoagulation should be continued for 2 to 3 months in patients without documented thromboembolic events or 3 to 6 months for patients with associated thrombosis. Patients should be instructed to avoid heparin for life."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"69aa4b",
"children":[
"Heparin-induced thrombocytopenia should be suspected in any patient treated with heparin whose platelet count decreases by greater than 50% from baseline or is less than 150,000/μL (150 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)."
]
},
{
"type":"keypoint",
"hlId":"3cd7be",
"hvc":true,
"children":[
"The 4T scoring algorithm should be used to stratify the likelihood of heparin-induced thrombocytopenia, and heparin should be discontinued and an alternate anticoagulant started for patients with intermediate or high risk for disease while awaiting confirmatory test results."
]
},
{
"type":"keypoint",
"hlId":"63890c",
"hvc":true,
"children":[
"Most patients taking heparin who develop thrombocytopenia but have a low 4T score need no further evaluation."
]
},
{
"type":"keypoint",
"hlId":"47269d",
"children":[
"Diagnosis of heparin-induced thrombocytopenia requires a screening test (enzyme-linked immunosorbent assay for platelet factor 4 antibodies) followed by a confirmatory test (serotonin release assay or heparin-induced platelet aggregation assay)."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s6_3_2_4",
"title":{
"__html":"Thrombotic Thrombocytopenic Purpura"
},
"titleNode":{
"type":"section-title",
"hlId":"7dbb60",
"children":[
"Thrombotic Thrombocytopenic Purpura"
]
},
"children":[
{
"type":"p",
"hlId":"ee4802",
"children":[
"Patients with TTP present with MAHA and thrombocytopenia. Acquired TTP is caused by a deficiency in the metalloprotease ADAMTS13, which is responsible for cleaving high-molecular-weight vWF multimers. These multimers accumulate, generating platelet-rich thrombi in small vessels. These thrombi consume platelets and shear erythrocytes, fragmenting them into schistocytes (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_hm_f21",
"wrapId":"4",
"children":[
"Figure 21"
]
}
]
},
")"
]
},
" and may cause end-organ injury. Autoantibodies to ADAMTS13 are responsible for the deficiency in most patients, but hereditary TTP has been reported in some. Drugs such as ticlopidine, quinine, cyclosporine, gemcitabine, and vascular endothelial growth factor inhibitors (such as bevacizumab) can cause TTP. Drug abuse with oxymorphone, 3,4-methylenedioxymethamphetamine (ecstasy), and cocaine has also been reported to cause TTP."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_b_hm_f21"
]
},
{
"type":"p",
"hlId":"45e478",
"children":[
"Acquired TTP manifests as MAHA (evidenced by elevated lactate dehydrogenase and decreased haptoglobin levels, schistocytes on peripheral blood smear, and a negative direct antiglobulin [Coombs] test result) and thrombocytopenia (with normal coagulation study results). An ADAMTS13 level less than 10% supports the diagnosis; an ADAMTS13 level greater than 50% should suggest an alternate diagnosis. The PLASMIC score is useful in guiding diagnosis while awaiting ADAMTS 13 level results ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t20",
"wrapId":"5",
"children":[
"Table 20"
]
}
]
},
")"
]
},
". The clinical picture is described in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t21",
"wrapId":"5",
"children":[
"Table 21"
]
}
]
},
". All patients have MAHA and thrombocytopenia, but only 5% of patients present with all the aforementioned signs. The mortality rate associated with TTP is high, so treatment must begin immediately without waiting for ADAMTS13 test results. Treatment is successful in 85% of patients."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_b_hm_t20",
"mk19_b_hm_t21"
]
},
{
"type":"p",
"hlId":"ecc294",
"children":[
"Initial treatment involves therapeutic plasma exchange (PLEX) to remove the high-molecular-weight vWF multimers and replace the deficient ADAMTS13 (plasma infusion, although not a definitive treatment, can be started if PLEX is delayed). Glucocorticoids are added to decrease autoantibody production. Rituximab (a monoclonal anti-CD20 B-cell antibody) is added to further suppress autoantibody production and to decrease the risk of recurrence. Caplacizumab (a monoclonal antibody against vWF) can be used to treat patients with severe hemolysis, severe thrombocytopenia, or significant end-organ injury. Caplacizumab is started on the first day of PLEX and continued until 30 days after the final treatment. Remission is defined by a normalization of the platelet count and is usually seen after 7 to 10 PLEX treatments."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"820994",
"children":[
"All patients with acquired thrombotic thrombocytopenic purpura have microangiopathic hemolytic anemia and thrombocytopenia; other clinical features may include fever, kidney disease, and fluctuating neurologic abnormalities."
]
},
{
"type":"keypoint",
"hlId":"5923a5",
"children":[
"The mortality rate associated with thrombotic thrombocytopenic purpura is high, so treatment with therapeutic plasma exchange should be started without awaiting laboratory results confirming ADAMTS13 deficiency."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s6_3_2_5",
"title":{
"__html":"Hemolytic Uremic Syndrome"
},
"titleNode":{
"type":"section-title",
"hlId":"7b5f9a",
"children":[
"Hemolytic Uremic Syndrome"
]
},
"children":[
{
"type":"p",
"hlId":"57ba90",
"children":[
"Hemolytic uremic syndrome (HUS) is characterized by thrombocytopenia, MAHA, and acute kidney injury. Classic HUS presents after an acute diarrheal illness caused by enterotoxin-producing ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Escherichia coli"
]
},
" O157:H7 (other strains have also been implicated). Diagnosis is confirmed by stool culture and polymerase chain reaction for Shiga toxin or O157:H7 antigen testing. Management is supportive with fluids and transfusions as needed. Antibiotics do not alter the disease course. Patients with classic HUS have a 4% associated mortality rate, and long-term sequelae include hypertension and chronic kidney disease. Atypical HUS manifests without diarrhea and may be caused by complement dysregulation or may occur secondary to drugs (see drugs listed in the TTP section previously), systemic lupus erythematosus, or other infection (HIV, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Streptococcus pneumoniae"
]
},
"). In severe disease or when the distinction from TTP is unclear, treatment with plasma exchange should begin immediately, adding eculizumab (a monoclonal antibody that binds to complement C5 and prevents generation of the membrane attack unit, C5b-9) if atypical HUS is suspected. Drug-induced HUS is managed supportively with drug avoidance."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"c6a486",
"children":[
"Classic hemolytic uremic syndrome is usually caused by enterotoxin-producing ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Escherichia coli"
]
},
", and management is supportive for most patients; antibiotics do not alter the natural disease course."
]
}
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s6_4",
"title":{
"__html":"Qualitative Platelet Disorders"
},
"titleNode":{
"type":"section-title",
"hlId":"c4688d",
"children":[
"Qualitative Platelet Disorders"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_hm_s6_4_1",
"title":{
"__html":"Acquired Platelet Dysfunction"
},
"titleNode":{
"type":"section-title",
"hlId":"c20df9",
"children":[
"Acquired Platelet Dysfunction"
]
},
"children":[
{
"type":"p",
"hlId":"f6e5ee",
"children":[
"Patients presenting with mucocutaneous bleeding and normal complete blood count, prothrombin time, and activated partial thromboplastin time should be evaluated for platelet dysfunction, which can result from hereditary or acquired disorders ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_hm_t22",
"wrapId":"6",
"children":[
"Table 22"
]
}
]
},
")"
]
},
". Von Willebrand disease is a common inherited cause of coagulation factor deficiency leading to platelet dysfunction (see ",
{
"type":"cross-reference",
"target":"mk19_b_hm_s7_3_2",
"children":[
"Bleeding Disorders"
]
},
"). Management of drug-induced platelet dysfunction depends on the clinical situation. The decision to reverse antiplatelet medication must balance the risks of thrombosis against the severity of the bleeding; if bleeding is significant, an alternative cause should be sought because symptoms of drug-induced platelet dysfunction are usually mild. Acute bleeding can be managed with platelet transfusions, but complete reversal of antiplatelet agents may be detrimental if the therapy is lifesaving. For example, aspirin for primary prevention of atherosclerotic cardiovascular disease can be safely discontinued if the patient is bleeding; however, dual antiplatelet therapy in patients with recently placed cardiac stents may be lifesaving, and bleeding management requires cardiology evaluation before reversing the medications. The P2Y",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"12"
]
},
" receptor antagonists can be withheld while aspirin is continued and resumed after adequate hemostasis is achieved. When antiplatelet agents are potentially lifesaving, bleeding may be controlled by other means (such as endoscopic management of bleeding ulcers)."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_b_hm_t22"
]
},
{
"type":"p",
"hlId":"737414",
"children":[
"Minor dental procedures or menorrhagia can be managed with antifibrinolytic agents (tranexamic acid or ε-aminocaproic acid)."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s6_4_2",
"title":{
"__html":"Platelet Function Testing"
},
"titleNode":{
"type":"section-title",
"hlId":"4d2d65",
"children":[
"Platelet Function Testing"
]
},
"children":[
{
"type":"p",
"hlId":"b8f30c",
"children":[
"Platelet function can be assessed by a variety of laboratory tests. A platelet function analyzer can be used as an initial screening test, replacing the traditional bleeding time. The test is run on a citrated blood sample exposed to collagen and either epinephrine or adenosine diphosphate. It is a sensitive test for von Willebrand disease and will detect abnormalities caused by antiplatelet medications. A modified platelet aggregometry device using a platelet activator can measure the amount of GPIIb/IIa receptor blockade by aspirin or P2Y",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"12"
]
},
" inhibitors. Classic platelet aggregometry tests platelet reactions to a variety of agonists and captures the primary and secondary aggregation waves. It is labor intensive and requires technical expertise, so it is not available in all hospitals. Thromboelastography and rotational thromboelastometry are bedside devices that analyze platelet function, coagulation, and clot stability; these may be useful as screening tests in patients with unexplained bleeding."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"14b59a",
"children":[
"Patients presenting with mucocutaneous bleeding and normal complete blood count, prothrombin time, and activated partial thromboplastin time should be evaluated for von Willebrand disease or acquired platelet dysfunction."
]
},
{
"type":"keypoint",
"hlId":"c1a44d",
"children":[
"The platelet function analyzer is a useful screening test for assessing qualitative platelet disorders."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s6_5",
"title":{
"__html":"Approach to the Patient With Thrombocytosis"
},
"titleNode":{
"type":"section-title",
"hlId":"09c7f0",
"children":[
"Approach to the Patient With Thrombocytosis"
]
},
"children":[
{
"type":"p",
"hlId":"713314",
"children":[
"Thrombocytosis refers to a platelet count exceeding 450,000/µL (450 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L). Primary causes of thrombocytosis are uncommon and include the myelodysplastic syndromes and myeloproliferative neoplasms (see ",
{
"type":"cross-reference",
"target":"mk19_b_hm_s2",
"children":[
"Hematopoietic Stem Cells and Their Disorders"
]
},
"). Secondary or reactive causes of thrombocytosis are more common and include iron deficiency, blood loss, hemolysis, medications, recent splenectomy, and inflammatory processes, especially infection and malignancy."
]
},
{
"type":"p",
"hlId":"4a86b2",
"children":[
"Evaluation begins with a careful history and physical examination directed toward possible causes, especially underlying inflammatory diseases and hematologic malignancies. Initial laboratory evaluation should include iron studies and inflammatory markers. Clonal disorders are often suggested by involvement of other cell lines, and testing for the ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"JAK2"
]
},
", ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"MPL"
]
},
", and calreticulin mutations may be appropriate."
]
},
{
"type":"p",
"hlId":"f745ee",
"children":[
"Treatment focuses on addressing the underlying cause. Thrombosis rarely occurs with reactive thrombocytosis, even at very high platelet counts. Elevated platelet counts associated with hematologic malignancies, however, are associated with thrombotic and hemorrhagic events, and treatment with antiplatelet agents, chemotherapy, and plateletpheresis may be necessary."
]
}
]
},
{
"type":"section",
"id":"mk19_b_hm_s6_6",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Bendapudi PK, Hurwitz S, Fry A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017;4:e157-e164. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28259520",
"target":"_blank"
},
"children":[
"PMID: 28259520"
]
},
" doi:10.1016/S2352-3026(17)30026-1"
]
},
{
"type":"reference",
"children":[
"Cheloff AZ, Al-Samkari H. Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease. J Blood Med. 2019;10:313-21. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31565009",
"target":"_blank"
},
"children":[
"PMID: 31565009"
]
},
" doi:10.2147/JBM.S191790"
]
},
{
"type":"reference",
"children":[
"Cooper N, Ghanima W. Immune thrombocytopenia. N Engl J Med. 2019;381:945-55. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31483965",
"target":"_blank"
},
"children":[
"PMID: 31483965"
]
},
" doi:10.1056/NEJMcp1810479"
]
},
{
"type":"reference",
"children":[
"Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2:3360-92. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30482768",
"target":"_blank"
},
"children":[
"PMID: 30482768"
]
},
" doi:10.1182/bloodadvances.2018024489"
]
},
{
"type":"reference",
"children":[
"Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019 Dec 10;3(23):3829-66. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31794604",
"target":"_blank"
},
"children":[
"PMID: 31794604"
]
},
" doi:10.1182/bloodadvances.2019000966"
]
},
{
"type":"reference",
"children":[
"Scully M, Cataland SR, Peyvandi F, et al; HERCULES Investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380:335-46. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30625070",
"target":"_blank"
},
"children":[
"PMID: 30625070"
]
},
" doi:10.1056/NEJMoa1806311"
]
},
{
"type":"reference",
"children":[
"Vrbensky JR, Moore JE, Arnold DM, et al. The sensitivity and specificity of platelet autoantibody testing in immune thrombocytopenia: a systematic review and meta-analysis of a diagnostic test. J Thromb Haemost. 2019;17:787-94. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30801909",
"target":"_blank"
},
"children":[
"PMID: 30801909"
]
},
" doi:10.1111/jth.14419"
]
},
{
"type":"reference",
"children":[
"Zwicker JI, Muia J, Dolatshahi L, et al; ART Investigators. Adjuvant low-dose rituximab and plasma exchange for acquired TTP [letter]. Blood. 2019;134:1106-09. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31331919",
"target":"_blank"
},
"children":[
"PMID: 31331919"
]
},
" doi:10.1182/blood.2019000795"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_b_hm_t19":{
"id":"mk19_b_hm_t19",
"number":19,
"bookId":"hm",
"title":{
"__html":"The 4T Scoring System for Predicting Heparin-Induced Thrombocytopenia and Thrombosis"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"c158f3",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 19. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t19"
}
]
},
"The 4T Scoring System for Predicting Heparin-Induced Thrombocytopenia and Thrombosis"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ef0f9e",
"class":"col hd l",
"children":[
"4 Ts"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7d62e6",
"class":"col hd l",
"children":[
"2 Points"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"33c4a0",
"class":"col hd l",
"children":[
"1 Point"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"078e22",
"class":"col hd l",
"children":[
"0 Points"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"78f621",
"class":"cell txt l",
"children":[
"Thrombocytopenia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6f3e7f",
"class":"cell txt l",
"children":[
"Platelet count decrease >50% and platelet nadir ≥20,000/μL (20 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8ba9c2",
"class":"cell txt l",
"children":[
"Platelet count decrease 30%-50% or platelet nadir 10,000-19,000/μL (10-19 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d8b456",
"class":"cell txt l",
"children":[
"Platelet count decrease <30% or platelet nadir <10,000/μL (10 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eaacab",
"class":"cell txt l",
"children":[
"Timing of platelet count decrease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d9bc6b",
"class":"cell txt l",
"children":[
"Clear onset between days 5-10 or platelet count decrease ≤1 day (with heparin exposure within 30 days)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2572a8",
"class":"cell txt l",
"children":[
"Consistent with platelet count decrease between days 5-10, but unclear (e.g., missing platelet counts); onset after day 10; or decrease ≤1 day (heparin exposure 30-100 days ago)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"836194",
"class":"cell txt l",
"children":[
"Platelet count decrease <4 days without recent exposure"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dfe7a2",
"class":"cell txt l",
"children":[
"Thrombosis or other sequelae"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4d1fd6",
"class":"cell txt l",
"children":[
"New thrombosis (confirmed); skin necrosis; acute systemic reaction after intravenous unfractionated heparin bolus"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8317e9",
"class":"cell txt l",
"children":[
"Progressive or recurrent clot; nonnecrotizing (e.g., erythematous) skin lesions; suspected thrombosis (not proved)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6adf97",
"class":"cell txt l",
"children":[
"None"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4e41d6",
"class":"cell txt l",
"children":[
"Other causes for thrombocytopenia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"643065",
"class":"cell txt l",
"children":[
"None apparent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7ed6c3",
"class":"cell txt l",
"children":[
"Possible"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1ab1ff",
"class":"cell txt l",
"children":[
"Definite"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"High probability: 6-8 points."
],
[
"Intermediate probability: 4-5 points."
],
[
"Low probability: 0-3 points."
]
]
},
"mk19_b_hm_t20":{
"id":"mk19_b_hm_t20",
"number":20,
"bookId":"hm",
"title":{
"__html":"PLASMIC Score<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"580edf",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 20. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t20"
}
]
},
"PLASMIC Score",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7a1f72",
"class":"col hd l",
"children":[
"Clinical Feature"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"75dd5f",
"class":"col hd l",
"children":[
"Points"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d9e03f",
"class":"cell txt l",
"children":[
"Platelet count <30,000/μL (30 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4d102d",
"class":"cell txt l",
"children":[
"Hemolysis",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c8264c",
"class":"cell txt l",
"children":[
"No active cancer"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0f52b3",
"class":"cell txt l",
"children":[
"No history of organ or stem cell transplantation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9cadbd",
"class":"cell txt l",
"children":[
"Mean corpuscular volume <90 fL"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dc79a8",
"class":"cell txt l",
"children":[
"INR <1.5"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6ab765",
"class":"cell txt l",
"children":[
"Creatinine <2 mg/dL (177 μmol/L)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"PLASMIC refers to the score's seven components: ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"P"
]
},
"latelet count; combined hemo",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"L"
]
},
"ysis variable; absence of ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"A"
]
},
"ctive cancer; absence of ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"S"
]
},
"tem-cell or solid-organ transplant; ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"M"
]
},
"CV; ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"I"
]
},
"NR; ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"C"
]
},
"reatinine."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"The presence of schistocytes is a precondition for applying the PLASMIC score."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Reticulocytes >2.5% of erythrocytes; indirect bilirubin >2 mg/dL (34.2 μmol/L), haptoglobin <50 mg/dL."
],
[
"Low risk: 0-4 points."
],
[
"Intermediate risk: 5 points."
],
[
"High risk: 6-7 points."
]
]
},
"mk19_b_hm_t21":{
"id":"mk19_b_hm_t21",
"number":21,
"bookId":"hm",
"title":{
"__html":"Clinical Characteristics of Thrombotic Thrombocytopenic Purpura"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"46ce90",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 21. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t21"
}
]
},
"Clinical Characteristics of Thrombotic Thrombocytopenic Purpura"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7962dd",
"class":"col hd l",
"children":[
"Clinical Features"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c48c4c",
"class":"col hd l",
"children":[
"Laboratory Findings/Pathologic Explanation"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"befbe8",
"class":"cell txt l",
"children":[
"Pallor and fever"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"214110",
"class":"cell txt l",
"children":[
"Microangiopathic hemolytic anemia in 100% of patients (schistocytes); fever likely from microinfarcts"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cf84f9",
"class":"cell txt l",
"children":[
"Bruising, petechiae"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"637723",
"class":"cell txt l",
"children":[
"Thrombocytopenia in 100% of patients; normal prothrombin time, activated partial thromboplastin time, and fibrinogen level"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dfc29b",
"class":"cell txt l",
"children":[
"Kidney injury"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6df74b",
"class":"cell txt l",
"children":[
"Mild kidney disease, proteinuria, hematuria from microthrombi"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7affb9",
"class":"cell txt l",
"children":[
"Fluctuating neurologic findings (confusion, headache, transient numbness, coma)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"311c49",
"class":"cell txt l",
"children":[
"CT scan may demonstrate cerebrovascular accident; transient microthrombi lead to reversible findings"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"279c03",
"class":"cell txt l",
"children":[
"Nausea, vomiting, diarrhea"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cd822e",
"class":"cell txt l",
"children":[
"Bowel ischemia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7cb82e",
"class":"cell txt l",
"children":[
"Chest pain, arrhythmia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"496e40",
"class":"cell txt l",
"children":[
"Myocardial injury; abnormal findings on electrocardiogram, troponin elevation"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_hm_t22":{
"id":"mk19_b_hm_t22",
"number":22,
"bookId":"hm",
"title":{
"__html":"Causes of Platelet Dysfunction"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"f5d4e4",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 22. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_hm_t22"
}
]
},
"Causes of Platelet Dysfunction"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"col hd l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"007cc9",
"class":"col hd l",
"children":[
"Severity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4c4ac0",
"class":"col hd l",
"children":[
"Treatment"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"4"
},
"children":[
" ",
{
"type":"p",
"hlId":"ffcdc2",
"class":"col hd l",
"children":[
"Congenital Platelet Defects"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a9eaf6",
"class":"cell txt l",
"children":[
"Glanzmann thrombasthenia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3cf935",
"class":"cell txt l",
"children":[
"Defect in glycoprotein IIb-IIIa"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a6b2b9",
"class":"cell txt l",
"children":[
"Severe"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b4c27a",
"class":"cell txt l",
"children":[
"Platelets or recombinant factor VIIa, ε-aminocaproic acid"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6fb878",
"class":"cell txt l",
"children":[
"Bernard-Soulier syndrome"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1c0eeb",
"class":"cell txt l",
"children":[
"Defect in glycoprotein Ib-IX"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a6b2b9",
"class":"cell txt l",
"children":[
"Severe"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fd5e82",
"class":"cell txt l",
"children":[
"Platelets, ε-aminocaproic acid"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d61dab",
"class":"cell txt l",
"children":[
"Wiskott-Aldrich syndrome"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8589db",
"class":"cell txt l",
"children":[
"Triad of eczema, thrombocytopenia, immunodeficiency"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1eb79d",
"class":"cell txt l",
"children":[
"Moderate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fd5e82",
"class":"cell txt l",
"children":[
"Platelets, ε-aminocaproic acid"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7dccda",
"class":"cell txt l",
"children":[
"Gray platelet syndrome"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4f866",
"class":"cell txt l",
"children":[
"Patients may develop myelofibrosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1eb79d",
"class":"cell txt l",
"children":[
"Moderate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fd5e82",
"class":"cell txt l",
"children":[
"Platelets, ε-aminocaproic acid"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d542af",
"class":"cell txt l",
"children":[
"Storage pool disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5ef4ac",
"class":"cell txt l",
"children":[
"Collection of diseases characterized by defect in platelet granules"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2eb5e4",
"class":"cell txt l",
"children":[
"Moderate to mild"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"19eda4",
"class":"cell txt l",
"children":[
"Platelets, ε-aminocaproic acid; some may respond to desmopressin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"4"
},
"children":[
" ",
{
"type":"p",
"hlId":"604208",
"class":"col hd l",
"children":[
"Acquired Platelet Defects"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4ae306",
"class":"cell txt l",
"children":[
"Uremia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fb9f19",
"class":"cell txt l",
"children":[
"Does not correlate with severity of kidney disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d14fbc",
"class":"cell txt l",
"children":[
"Mild"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"19134b",
"class":"cell txt l",
"children":[
"Dialysis, desmopressin, ε-aminocaproic acid"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"21be40",
"class":"cell txt l",
"children":[
"Liver disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8857d1",
"class":"cell txt l",
"children":[
"Also associated with hyperfibrinolysis and coagulopathy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a7d3c5",
"class":"cell txt l",
"children":[
"Mild to severe"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fd5e82",
"class":"cell txt l",
"children":[
"Platelets, ε-aminocaproic acid"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a483a2",
"class":"cell txt l",
"children":[
"Myeloproliferative neoplasms"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"94a963",
"class":"cell txt l",
"children":[
"If platelet count is >1-1.5 million/μL (1000-1500 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L), may be associated with acquired von Willebrand disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a7d3c5",
"class":"cell txt l",
"children":[
"Mild to severe"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4b7813",
"class":"cell txt l",
"children":[
"Before surgical procedures, normalize the platelet count"
]
},
" ",
{
"type":"p",
"hlId":"652a0a",
"class":"cell txt l",
"children":[
"Platelet transfusion may be necessary if bleeding occurs"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b562a7",
"class":"cell txt l",
"children":[
"Post-cardiac bypass"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"07b114",
"class":"cell txt l",
"children":[
"Multifactorial, including interaction with bypass machine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d14fbc",
"class":"cell txt l",
"children":[
"Mild"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"661c33",
"class":"cell txt l",
"children":[
"Platelets, if necessary"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d7b2b3",
"class":"cell txt l",
"children":[
"Antiplatelet drugs"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dd3b02",
"class":"cell txt li",
"children":[
"IIb-IIIa inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"31306b",
"class":"cell txt l",
"children":[
"Antiplatelet effects range from irreversible (abciximab) to reversible (eptifibatide and tirofiban)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a6b2b9",
"class":"cell txt l",
"children":[
"Severe"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"256c18",
"class":"cell txt l",
"children":[
"Platelets"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c40028",
"class":"cell txt li",
"children":[
"Aspirin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4db0fb",
"class":"cell txt l",
"children":[
"Irreversible"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d14fbc",
"class":"cell txt l",
"children":[
"Mild"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"661c33",
"class":"cell txt l",
"children":[
"Platelets, if necessary"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ece3",
"class":"cell txt li",
"children":[
"Clopidogrel"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4db0fb",
"class":"cell txt l",
"children":[
"Irreversible"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d14fbc",
"class":"cell txt l",
"children":[
"Mild"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"661c33",
"class":"cell txt l",
"children":[
"Platelets, if necessary"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d3bf03",
"class":"cell txt li",
"children":[
"NSAIDs"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10d85d",
"class":"cell txt l",
"children":[
"Temporary"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d14fbc",
"class":"cell txt l",
"children":[
"Mild"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8bc851",
"class":"cell txt l",
"children":[
"None usually needed"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"32ad00",
"class":"cell txt l",
"children":[
"Other drugs and herbs (β-lactams, vitamin E, ginkgo, turmeric, garlic, Chinese tree fungus)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d14fbc",
"class":"cell txt l",
"children":[
"Mild"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8bc851",
"class":"cell txt l",
"children":[
"None usually needed"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
}
}
}